Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
MWN-AI** Summary
Dentsply Sirona Inc. (Nasdaq: XRAY) has announced the appointment of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors, effective February 27, 2026. These appointments are significant steps aimed at enhancing the company’s strategic and financial governance capabilities, particularly as it implements its Return-to-Growth action plan.
Jim Forbes brings 30 years of healthcare investment banking experience, having previously served as Vice Chairman of Investment Banking at Morgan Stanley and held senior roles at UBS and Bank of America Merrill Lynch. He is known for advising healthcare companies on complex strategic transactions and capital market dealings. Forbes will serve on the Compensation & Human Capital Committee.
Brian McKeon adds a robust financial and operational background with 25 years of experience as CFO for three public companies. His most recent role was as Executive Vice President, CFO, and Treasurer at IDEXX Laboratories, where he played a crucial role in the company's growth and market leadership. McKeon will join the Audit and Finance Committee as well as the Science and Technology Committee.
Gregory T. Lucier, Chairman of the Board, emphasized that the addition of Forbes and McKeon follows the recent appointment of Don Zurbay and marks an important enhancement to the Board’s capabilities to support ongoing management strategies focused on operational performance and shareholder value.
Additionally, Willie Deese has announced his retirement from the Board, concluding 15 years of service during a transformative period for the company. The Board expressed gratitude for his contributions.
Dentsply Sirona, headquartered in Charlotte, NC, is a leading manufacturer in the dental industry, developing a wide range of dental products and technologies that advance patient care and dental practices.
MWN-AI** Analysis
The recent appointments of James Forbes and Brian McKeon to the Board of Directors at Dentsply Sirona (Nasdaq: XRAY) signal a strategic bolstering of the company’s leadership, particularly as it embarks on its "Return-to-Growth" action plan. The presence of individuals with deep financial and healthcare industry experience offers a timely opportunity for current and prospective investors to reassess their positions in Dentsply Sirona.
Forbes' extensive background in healthcare investment banking, combined with McKeon's financial stewardship and operational expertise, suggests that Dentsply Sirona is prioritizing a disciplined approach to strategic decisions and capital allocation going forward. Given Forbes’ prior high-stakes roles at Morgan Stanley and Bank of America Merrill Lynch, his insights could potentially unlock new avenues for growth and strategic partnerships, thereby enhancing firm valuation in the long run.
With McKeon’s history as CFO and his rigorous financial management experience, he is well-equipped to lead the company's financial and audit strategies. His commitment to optimizing capital deployment aligns with Dentsply Sirona's ambitions to increase shareholder value, especially in a competitive sector where innovative financial strategies are vital for sustained dominance.
Investors should consider this Board enhancement as a pivotal moment; the renewed governance capabilities and expertise signal a proactive approach to tackling market challenges. With the anticipated internal focus on operational performance and strategic execution, Dentsply Sirona could be well-positioned for recovery and expansion.
However, it’s crucial to remain cautious. Investors should keep an eye on market reactions to these changes and monitor updates related to the company's execution of its growth strategies. Overall, the appointments can be seen as a positive move, advocating a potentially favorable outlook for the company’s stock in the face of evolving market dynamics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026.
Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior executive roles at UBS and Bank of America Merrill Lynch. Mr. Forbes will serve on the Company’s Compensation & Human Capital Committee.
Mr. McKeon brings deep financial and operational expertise, having served 25 years as the Chief Financial Officer of three public companies and as a member of several public company boards of directors. Most recently, he held the position of Executive Vice President, CFO, and Treasurer and head of strategy for IDEXX Laboratories, where he helped deliver exceptional value creation with multi-year growth and expansion of key market leadership positions. Mr. McKeon will join the Company’s Audit and Finance Committee and Science and Technology Committee.
“Following the recent appointment of Don Zurbay, who adds deep dental experience to the Board, the appointments of Jim and Brian mark an important next step in continuing to strengthen the Board’s strategic, financial and governance capabilities to execute our Return-to-Growth action plan,” said Gregory T. Lucier, Chairman of the Board of Dentsply Sirona. “Jim brings extensive experience advising healthcare companies on complex strategic and capital allocation decisions, while Brian contributes significant public company CFO and governance expertise. Together, their complementary perspectives will further strengthen the Board’s ability to support the management team in driving disciplined execution, operational performance and sustainable long-term growth.”
“I am honored to join the Board at such an important time for the Company,” said Mr. Forbes. “I look forward to leveraging my experience in finance across the healthcare industry to support the Board and management team as they continue to strengthen the Company’s strategic capabilities and execute on its Return-to-Growth strategy.”
“I am pleased to join the Board and contribute to the Company’s next phase of growth,” said Mr. McKeon. “Disciplined strategic choices, capital allocation and strong financial stewardship are essential to delivering durable shareholder value. I look forward to working with the Board and management team to enhance financial rigor and optimize capital deployment.”
In connection with the Board’s ongoing refreshment process, Willie Deese has informed the Board of his desire to retire from the Board and not stand for re-election at this year’s annual shareholders’ meeting.
“Willie has been a valuable member of our Board, providing thoughtful counsel and steady leadership during a period of significant transformation,” said Mr. Lucier. “On behalf of the Board and myself personally, I want to sincerely thank him for his 15 years of service to the Company, and we are grateful for his contributions.”
About James (Jim) Forbes
Mr. Forbes has more than three decades of investment banking experience, with a primary focus on the healthcare sector. He has held senior leadership roles at Morgan Stanley, UBS, and Bank of America Merrill Lynch, including serving as Co-Head of Global Healthcare Investment Banking at Merrill Lynch. Over the course of his career, he has advised on financing transactions totaling more than $200 billion and executed M&A transactions exceeding $100 billion in value. Mr. Forbes has extensive expertise in capital allocation and a strong track record advising healthcare companies on complex strategic transactions. He has also served on multiple boards in connection with his investment activities, including HCA Healthcare and several private equity portfolio companies, where he provided guidance on strategic financial decisions and corporate governance matters. Mr. Forbes holds a bachelor’s degree from Loyola University Maryland, Baltimore.
About Brian P. McKeon
Mr. McKeon has 25 years of experience as a public company Chief Financial Officer and nearly 20 years of public company board experience. He has broad strategic, financial and operational leadership expertise across high-growth, global, and innovative companies. Most recently, he served as Executive Vice President, Chief Financial Officer, and Treasurer of IDEXX Laboratories, Inc. Mr. McKeon currently serves on the board of directors of Alkermes plc and National Veterinary Associates and previously served as a director of athenahealth, Inc. and IDEXX Laboratories, Inc. His experience spans strategy, finance, operational execution, and governance in complex public company environments. Mr. McKeon holds an M.B.A. from Harvard University, and a bachelor’s degree in accounting from the University of Connecticut.
About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact Information
Investors:
Wade Moody
Senior Manager, Investor Relations
InvestorRelations@dentsplysirona.com
FAQ**
How do the recent appointments of James (Jim) D. Forbes and Brian P. McKeon to DENTSPLY SIRONA Inc. XRAY's Board of Directors align with the company's Return-to-Growth action plan?
What specific strategic and financial expertise do Jim Forbes and Brian McKeon bring to DENTSPLY SIRONA Inc. XRAY, and how might this influence the company's future operations?
Given Willie Deese's retirement, how does DENTSPLY SIRONA Inc. XRAY plan to maintain board effectiveness and governance during this transition?
What potential impacts could the board changes at DENTSPLY SIRONA Inc. XRAY have on shareholder value and capital allocation strategies moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about DENTSPLY SIRONA Inc. (NASDAQ: XRAY).
NASDAQ: XRAY
XRAY Trading
-1.75% G/L:
$12.485 Last:
1,340,814 Volume:
$12.50 Open:
